New insulin vs. Brand-Name: a Head-to-Head test in healthy volunteers

NCT ID NCT07608692

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tested how a new insulin injection (USLIN®R) compares to a standard brand (Novolin®R) in 32 healthy men. Each participant received both insulins at different times to measure how quickly and effectively they work. The goal is to see if the new insulin is similar enough to offer a reliable alternative for diabetes care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Human insulin injection (USLIN®R and Novolin®R)

What this could lead to

If successful, this study could show that the test insulin works similarly to a well-known brand, potentially offering a new, comparable option for people with diabetes.

What could go wrong

This is an early-phase trial in only 32 healthy men, not people with diabetes. Results may not apply to real-world patients, and the test insulin might still differ in safety or effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS AND PHARMACODYNAMICS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • 28 Baofeng Road, Qiaokou District

    Wuhan, Hubei, 430000, China